Abstract
Background The metabotropic glutamate receptor, subtype 5 (GRM5) regulates cell excitability and neurotransmission and has been suggested to play a modifying role in several neuropsychiatric and neurodegenerative disorders, including Parkinson’s disease (PD). The observation that GRM5 inhibitors ameliorate symptoms and slow the degradation of nigrostriatal dopamine neurons in rodent models of PD suggests that low expression of GRM5 may also reduce symptoms in human patients and, possibly, slow the development of the disease. The goal of the present study is quantify common variation of GRM5 mRNA expression in human brain and identify haplotypes or combinations of genotypes that correlate with mRNA expression. Haplotypes and genotype combinations that predict mRNA expression should be useful as markers in genetic association studies aimed at detecting possible contributions of GRM5 to PD and other disorders.
Highlights
The metabotropic glutamate receptor, subtype 5 (GRM5) regulates cell excitability and neurotransmission and has been suggested to play a modifying role in several neuropsychiatric and neurodegenerative disorders, including Parkinson’s disease (PD)
The goal of the present study is quantify common variation of GRM5 mRNA expression in human brain and identify haplotypes or combinations of genotypes that correlate with mRNA expression
Haplotypes and genotype combinations that predict mRNA expression should be useful as markers in genetic association studies aimed at detecting possible contributions of GRM5 to PD and other disorders
Summary
The metabotropic glutamate receptor, subtype 5 (GRM5) regulates cell excitability and neurotransmission and has been suggested to play a modifying role in several neuropsychiatric and neurodegenerative disorders, including Parkinson’s disease (PD). The observation that GRM5 inhibitors ameliorate symptoms and slow the degradation of nigrostriatal dopamine neurons in rodent models of PD suggests that low expression of GRM5 may reduce symptoms in human patients and, possibly, slow the development of the disease. The goal of the present study is quantify common variation of GRM5 mRNA expression in human brain and identify haplotypes or combinations of genotypes that correlate with mRNA expression. Haplotypes and genotype combinations that predict mRNA expression should be useful as markers in genetic association studies aimed at detecting possible contributions of GRM5 to PD and other disorders
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
